Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

- Documented evidence of active multiple myeloma:

- Newly diagnosed, not candidate for transplant

- Relapsed/refractory who have received up to 3 prior lines of therapy

- Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:

- Not refractory to prior Lenalidomide which is defined as no progression while
receiving Lenalidomide or within 60 days of last dose of Lenalidomide

- Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event
(AE)

Exclusion Criteria:

- Target Disease Exceptions

- Plasma cell leukemia

- Monoclonal gammopathy of undetermined significance (MGUS)

- Smoldering Myeloma

- Primary amyloidosis

- Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes
(POEMS) syndrome